Which has better valuation and earnings, PROF or SIBN?

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $16.10M 15.67 -$42.57M -$0.98 N/A SiBone $200.93M 4.28 -$18.90M -$0.34 N/A

Is PROF or SIBN more profitable?

SiBone has a net margin of -6.85% compared to Profound Medical's net margin of -171.57%. SiBone's return on equity of -8.23% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets Profound Medical -171.57% -63.03% -51.24% SiBone -6.85% -8.23% -6.07%

Does the media prefer PROF or SIBN?

In the previous week, SiBone had 2 more articles in the media than Profound Medical. MarketBeat recorded 13 mentions for SiBone and 11 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.48 beat SiBone's score of 0.35 indicating that Profound Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SiBone 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, INMD or PROF?

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $374.63M 2.18 $93.83M $1.23 11.55 Profound Medical $16.10M 15.67 -$42.57M -$0.98 N/A

Is INMD or PROF more profitable?

InMode has a net margin of 20.69% compared to Profound Medical's net margin of -171.57%. InMode's return on equity of 11.99% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% Profound Medical -171.57% -63.03% -51.24%

Does the media refer more to INMD or PROF?

In the previous week, Profound Medical had 8 more articles in the media than InMode. MarketBeat recorded 11 mentions for Profound Medical and 3 mentions for InMode. Profound Medical's average media sentiment score of 0.48 beat InMode's score of 0.28 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor VREX or PROF?

In the previous week, Profound Medical had 8 more articles in the media than Varex Imaging. MarketBeat recorded 11 mentions for Profound Medical and 3 mentions for Varex Imaging. Varex Imaging's average media sentiment score of 0.67 beat Profound Medical's score of 0.48 indicating that Varex Imaging is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Varex Imaging 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor AVR or PROF?

In the previous week, Anteris Technologies Global had 15 more articles in the media than Profound Medical. MarketBeat recorded 26 mentions for Anteris Technologies Global and 11 mentions for Profound Medical. Anteris Technologies Global's average media sentiment score of 0.92 beat Profound Medical's score of 0.48 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 6 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PROF or ANGO?

In the previous week, AngioDynamics had 20 more articles in the media than Profound Medical. MarketBeat recorded 31 mentions for AngioDynamics and 11 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.48 beat AngioDynamics' score of 0.38 indicating that Profound Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral AngioDynamics 6 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Profound Medical (PROF) Competitors

$6.90 -0.01 (-0.14%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.92 +0.01 (+0.22%)

As of 10/9/2026 07:42 PM Eastern

Compare

PROF vs. SIBN, INMD, VREX, AVR, and ANGO

Should you buy Profound Medical stock or one of its competitors? Profound Medical's main competitors and comparable companies include SiBone (SIBN), InMode (INMD), Varex Imaging (VREX), Anteris Technologies Global (AVR), and AngioDynamics (ANGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Profound Medical compare to SiBone?

Profound Medical (NASDAQ:PROF) and SiBone (NASDAQ:SIBN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, SiBone had 2 more articles in the media than Profound Medical. MarketBeat recorded 13 mentions for SiBone and 11 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.48 beat SiBone's score of 0.35 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
SiBone	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Profound Medical has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, SiBone has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SiBone has a net margin of -6.85% compared to Profound Medical's net margin of -171.57%. SiBone's return on equity of -8.23% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
SiBone	-6.85%	-8.23%	-6.07%

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.67	-$42.57M	-$0.98	N/A
SiBone	$200.93M	4.28	-$18.90M	-$0.34	N/A

Profound Medical presently has a consensus price target of $11.50, suggesting a potential upside of 66.67%. SiBone has a consensus price target of $24.17, suggesting a potential upside of 24.76%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats Profound Medical on 11 of the 17 factors compared between the two stocks.

How does Profound Medical compare to InMode?

InMode (NASDAQ:INMD) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

InMode has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

In the previous week, Profound Medical had 8 more articles in the media than InMode. MarketBeat recorded 11 mentions for Profound Medical and 3 mentions for InMode. Profound Medical's average media sentiment score of 0.48 beat InMode's score of 0.28 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$374.63M	2.18	$93.83M	$1.23	11.55
Profound Medical	$16.10M	15.67	-$42.57M	-$0.98	N/A

InMode presently has a consensus price target of $16.00, suggesting a potential upside of 12.60%. Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 66.67%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

68.0% of InMode shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InMode has a net margin of 20.69% compared to Profound Medical's net margin of -171.57%. InMode's return on equity of 11.99% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
Profound Medical	-171.57%	-63.03%	-51.24%

Summary

InMode beats Profound Medical on 10 of the 16 factors compared between the two stocks.

How does Profound Medical compare to Varex Imaging?

Varex Imaging (NASDAQ:VREX) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Profound Medical has lower revenue, but higher earnings than Varex Imaging. Profound Medical is trading at a lower price-to-earnings ratio than Varex Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Varex Imaging	$844.60M	0.92	-$70.30M	$0.52	35.50
Profound Medical	$16.10M	15.67	-$42.57M	-$0.98	N/A

Varex Imaging has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Varex Imaging currently has a consensus target price of $16.88, suggesting a potential downside of 8.59%. Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 66.67%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than Varex Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Varex Imaging	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Varex Imaging has a net margin of 2.55% compared to Profound Medical's net margin of -171.57%. Varex Imaging's return on equity of 9.19% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Varex Imaging	2.55%	9.19%	4.13%
Profound Medical	-171.57%	-63.03%	-51.24%

In the previous week, Profound Medical had 8 more articles in the media than Varex Imaging. MarketBeat recorded 11 mentions for Profound Medical and 3 mentions for Varex Imaging. Varex Imaging's average media sentiment score of 0.67 beat Profound Medical's score of 0.48 indicating that Varex Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Varex Imaging	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

47.9% of Profound Medical shares are held by institutional investors. 4.6% of Varex Imaging shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Varex Imaging beats Profound Medical on 9 of the 17 factors compared between the two stocks.

How does Profound Medical compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Anteris Technologies Global has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

47.9% of Profound Medical shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profound Medical has a net margin of -171.57% compared to Anteris Technologies Global's net margin of -4,619.27%. Profound Medical's return on equity of -63.03% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%
Profound Medical	-171.57%	-63.03%	-51.24%

Profound Medical has higher revenue and earnings than Anteris Technologies Global. Profound Medical is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	345.45	-$94.14M	-$1.95	N/A
Profound Medical	$16.10M	15.67	-$42.57M	-$0.98	N/A

In the previous week, Anteris Technologies Global had 15 more articles in the media than Profound Medical. MarketBeat recorded 26 mentions for Anteris Technologies Global and 11 mentions for Profound Medical. Anteris Technologies Global's average media sentiment score of 0.92 beat Profound Medical's score of 0.48 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Anteris Technologies Global presently has a consensus price target of $14.00, suggesting a potential upside of 106.79%. Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 66.67%. Given Anteris Technologies Global's higher possible upside, equities research analysts clearly believe Anteris Technologies Global is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Profound Medical beats Anteris Technologies Global on 9 of the 17 factors compared between the two stocks.

How does Profound Medical compare to AngioDynamics?

Profound Medical (NASDAQ:PROF) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

AngioDynamics has a net margin of -10.12% compared to Profound Medical's net margin of -171.57%. AngioDynamics' return on equity of -4.43% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
AngioDynamics	-10.12%	-4.43%	-2.89%

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AngioDynamics has higher revenue and earnings than Profound Medical. AngioDynamics is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.67	-$42.57M	-$0.98	N/A
AngioDynamics	$320.17M	1.51	-$36.74M	-$0.78	N/A

In the previous week, AngioDynamics had 20 more articles in the media than Profound Medical. MarketBeat recorded 31 mentions for AngioDynamics and 11 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.48 beat AngioDynamics' score of 0.38 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
AngioDynamics	6 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Profound Medical presently has a consensus target price of $11.50, indicating a potential upside of 66.67%. AngioDynamics has a consensus target price of $19.50, indicating a potential upside of 69.27%. Given AngioDynamics' higher possible upside, analysts plainly believe AngioDynamics is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Profound Medical has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Summary

AngioDynamics beats Profound Medical on 11 of the 16 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROF vs. The Competition

Export

Metric	Profound Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$252.64M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-7.04	25.57	274.15	26.16
Price / Sales	15.67	83.25	635.98	113.06
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	3.77	5.93	11.21	6.34
Net Income	-$42.57M	$146.18M	$3.50B	$381.90M
7 Day Performance	18.15%	-0.38%	-0.90%	-1.41%
1 Month Performance	15.77%	-2.02%	-4.44%	-3.48%
1 Year Performance	17.55%	5.08%	6.96%	1.16%

Profound Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROF Profound Medical	2.855 of 5 stars	$6.90 -0.1%	$11.50 +66.7%	+4.1%	$252.64M	$16.10M	N/A	162	Trending News Analyst Upgrade
SIBN SiBone	3.4524 of 5 stars	$19.15 +2.1%	$24.17 +26.2%	+23.2%	$831.99M	$200.93M	N/A	376	News Coverage
INMD InMode	1.8452 of 5 stars	$14.22 +0.1%	$16.00 +12.5%	-10.6%	$816.51M	$370.49M	11.56	660
VREX Varex Imaging	2.2015 of 5 stars	$18.47 +0.1%	$16.88 -8.6%	+63.5%	$777.17M	$865M	35.52	2,400	Analyst Upgrade
AVR Anteris Technologies Global	2.8728 of 5 stars	$7.59 -1.9%	$16.00 +110.8%	+38.4%	$754.33M	$1.91M	N/A	174	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROF) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Competitors

PROF vs. SIBN, INMD, VREX, AVR, and ANGO

How does Profound Medical compare to SiBone?

Summary

How does Profound Medical compare to InMode?

Summary

How does Profound Medical compare to Varex Imaging?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Summary

How does Profound Medical compare to AngioDynamics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Competitors

PROF vs. SIBN, INMD, VREX, AVR, and ANGO

How does Profound Medical compare to SiBone?

Does the media prefer PROF or SIBN?

Which has more volatility and risk, PROF or SIBN?

Do institutionals & insiders hold more shares of PROF or SIBN?

Is PROF or SIBN more profitable?

Which has better valuation and earnings, PROF or SIBN?

Do analysts prefer PROF or SIBN?

Summary

How does Profound Medical compare to InMode?

Which has more risk & volatility, INMD or PROF?

Does the media refer more to INMD or PROF?

Which has better earnings and valuation, INMD or PROF?

Do analysts prefer INMD or PROF?

Do insiders & institutionals hold more shares of INMD or PROF?

Is INMD or PROF more profitable?

Summary

How does Profound Medical compare to Varex Imaging?

Which has higher earnings & valuation, VREX or PROF?

Which has more volatility and risk, VREX or PROF?

Do analysts prefer VREX or PROF?

Is VREX or PROF more profitable?

Does the media favor VREX or PROF?

Do institutionals & insiders hold more shares of VREX or PROF?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Which has more volatility & risk, AVR or PROF?

Do institutionals and insiders hold more shares of AVR or PROF?

Is AVR or PROF more profitable?

Which has preferable valuation & earnings, AVR or PROF?

Does the media favor AVR or PROF?

Do analysts prefer AVR or PROF?

Summary

How does Profound Medical compare to AngioDynamics?

Is PROF or ANGO more profitable?

Do institutionals & insiders have more ownership in PROF or ANGO?

Which has higher valuation & earnings, PROF or ANGO?

Does the media prefer PROF or ANGO?

Do analysts prefer PROF or ANGO?

Which has more risk and volatility, PROF or ANGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools